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Effectiveness results
The effectiveness results were as follows:
The final histologic diagnosis was carcinoma in 89% of women who underwent stereotactic biopsy and 74% of women who underwent surgical biopsy, (p=0.04, 95% CI: 1.0 -7.7).
Median histologic size of infiltrating carcinoma was 0.4 cm in women who underwent stereotactic biopsy and 0.5 cm in women who underwent surgical biopsy. The median number of operations was one with stereotactic biopsy and two with diagnostic surgical biopsy. The likelihood of undergoing a single operation was 68% with stereotactic biopsy and 38% with diagnostic surgical biopsy, (p<0.001) among all women and among women treated for breast cancer (71% versus 16%, p<0.001). Stereotactic 11-gauge vacuum-assisted biopsy as compared with 14-gauge automated core or 14-gauge vacuum-assisted biopsy was more likely to spare a surgical procedure, (77% versus 38%, p=0.0005).
Benign findings without atypia were found in 9% of women who underwent stereotactic biopsy and 24% of women who underwent surgical biopsy.
The likelihood of achieving tumour resection with clear margins at the first operation was greater if the initial diagnostic procedure was stereotactic rather than surgical biopsy, among all women with breast cancer (75% versus 22%, p<0.01, 95% CI: 4.0 -32.3), and among women treated with breast-conserving surgery (57% versus 33%, p=0.16, 95% CI: 0.7 -10.3).
Clinical conclusions
Stereotactic biopsy was more likely to achieve tumour resection with clear margins at the first operation than diagnostic surgical biopsy.
Measure of benefits used in the economic analysis
The authors did not report a summary health benefit and left outcomes disaggregated. Hence, a cost-consequences analysis was conducted.
Direct costs
Direct costs were not discounted due to the short time horizon of the study (less than one year). Quantities and costs were reported separately. Direct costs related to costs of stereotactic breast biopsy, and costs of needle localisation and surgical breast biopsy. The quantity/cost boundary adopted was that of the hospital. Costs were calculated using Medicare data. The price year was 2000.
